Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TrilynX: Debio 1143 (xevinapant) plus chemoradiotherapy in locally advanced head and neck cancer
jRCT2031210525Phase 3Completed
- Sponsor
- Merck KGaA
- Start
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing Xevinapant + cisplatin + IMRT followed by xevinapant with Placebo + cisplatin + IMRT followed by placebo (2 arms). Primary endpoint: Event-Free Survival. Started Feb 2022; status: completed.
02
Drugs
xevinapant
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCT2031210525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210525.